Skip to main content

Day: September 27, 2022

Real Brands Signs Definitive Agreement for the Acquisition of Boulder Botanical & Biosciences Laboratories Assets

Real Brands Inc. Real Brands signed the definitive agreement to acquire Boulder Botanical’s assets in Golden, Colorado, and will continue Boulder’s current herbal supplement, sports medicine and CBD manufacturing and distribution business that provides white-label products to many of the nation’s largest retail chains.$12 million transaction Provides Real Brands with world class R&D and manufacturing capabilities for 300% increase in production capacity and 150+ brands Specializes in sports medicine, health and wellness herbal supplements and CBD products Expands Real Brands’ distribution to major retail chains nationwideNorth Providence, RI, and Golden, CO, Sept. 27, 2022 (GLOBE NEWSWIRE) — Real Brands Inc. (OTCQB: RLBD) announced today that it has signed the definitive agreement for the acquisition of substantially...

Continue reading

Lincoln Tech Student Receives Mike Rowe Works Foundation Scholarship

Parsippany, NJ, Sept. 27, 2022 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (NASDAQ: LINC), a national leader in specialized technical training for more than 75 years, has announced that student Avery Hill has been selected to receive a Work Ethic Scholarship from the Mike Rowe Works Foundation. Hill, who is currently enrolled in the Heating, Ventilation and Air Conditioning career training program at Lincoln’s East Windsor, CT campus, was selected to receive the $5,000 scholarship as part of the Foundation’s efforts to promote career-focused education for students seeking to enter in-demand, hands-on trades. “Receiving the Mike Rowe scholarship means so much to me,” says Hill. “It feels good knowing I can graduate with less debt, and I’m so glad that I chose to pursue this training program at Lincoln Tech. My instructor...

Continue reading

Festi hf.: Guðrún Aðalsteinsdóttir to be the new CEO of Krónan ehf.

Guðrún Aðalsteinsdóttir, engineer, has been appointed as Krónan’s managing director. She will assume the position as of today, 27 September, 2022. She succeeds Ásta Sigríður Fjeldsted, who was appointed CEO of Festi, Krónan’s parent company, on 7 September. Guðrún has worked at Krónan for almost two years, most recently as director of digital development and improvement projects, and before that as director of procurement and product management. Guðrún is an operational engineer with an M.Sc. from the Technical University of Denmark (DTU). She previously worked as a director at Icelandair in the operations department, where she was responsible for, among other things, sales and service of the company’s aircraft, product development, purchasing, inventory management and related production. She also has international experience...

Continue reading

Karolinska Development’s portfolio company Modus Therapeutics has completed recruitment in a clinical phase 1b study of sevuparin

STOCKHOLM, SWEDEN September 27, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed the recruitment in a clinical phase 1b study of sevuparin, where the company’s lead asset sevuparin is being evaluated for the treatment of sepsis and septic shock. The randomized, placebo-controlled phase 1b study evaluates the effects of sevuparin in healthy volunteers after they have been induced with the bacterial toxin lipopolysaccharide (LPS), a provocation that is a well-established model for characterizing early stages of septic inflammation. The aim of the study is also to evaluate the safety profile of sevuparin when the substance is used in combination with heparin, a standard prophylactic, blood-thinning substance. “Modus Therapeutics’ drug candidate sevuparin has...

Continue reading

Foresight Solar & Technology VCT plc – Result of AGM

FORESIGHT SOLAR & TECHNOLOGY VCT PLC (“Company”)Legal Entity Identity number: 21380013CXOR8N6OD977AGM Statement The board of the Company (“Board”) is pleased to announce that at the Annual General Meeting of the Company held on 27 September 2022, all of the resolutions were passed on a unanimous show of hands. The voting was as follows:Resolution Votes For (including discretion) Votes Against1 – To receive the Annual Report and Accounts 2,355,749 45,0002 – To approve the Directors’ Remuneration Policy 2,279,790 104,5473 – To approve the Directors’ Remuneration Report 2,296,202 104,5474 – To re-elect Ernie Richardson as Director 2,342,282 50,2985 – To re-elect Timothy Dowlen as Director 2,313,847 63,9966 – To re-elect Carol Thompson as Director 2,316,760 50,2987 – To re-appoint Deloitte LLP as Auditor 2,312,851 61,6818...

Continue reading

SL Green Realty Corp. to Release Third Quarter 2022 Financial Results After Market Close on October 19, 2022

Conference Call to be Held on October 20, 2022 at 2:00 pm ET NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE: SLG), Manhattan’s largest office landlord, today announced that it will release its earnings for the third quarter of 2022 on Wednesday, October 19, 2022 after market close. The Company’s executive management team, led by Marc Holliday, Chairman and Chief Executive Officer, will host a conference call and audio webcast on Thursday, October 20, 2022 at 2:00 pm ET to discuss the financial results. Simultaneous with the earnings release, supplemental data will be made available in the Investors section of the SL Green Realty Corp. website at https://slgreen.com under “Financial Reports”. The live conference call will be webcast in listen-only mode and a replay will be available in the Investors...

Continue reading

Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD

ISELIN, N.J. and CONSHOHOCKEN, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, and AmerisourceBergen (NYSE: ABC), a global healthcare company and leader in specialty pharmaceutical distribution and services, announced today that they have entered into a strategic relationship in preparation for the anticipated commercial launch in the United States of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), if approved by the U.S. Food and Drug Administration (FDA). AmerisourceBergen will provide third-party logistics (3PL) services and distribution, as well as medical information and pharmacovigilance services in the United States. As Outlook Therapeutics...

Continue reading

Reklaim Signs Letter of Intent to Acquire Multimedia Lists Inc.

Multimedia Lists is cash flow positive and is expected to double Reklaim’s monthly revenue immediately upon the close of the transaction. NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) — via InvestorWire — Reklaim (OTCQB: MYIDF) (TSXV: MYID) (“Reklaim”), the destination for consumers to access and reclaim their data, announces it has entered into a non-binding letter of intent to purchase the assets of Multimedia Lists, Inc. (“MML”), a data broker currently operating in the United States (the “Transaction”). MML is a cash flow-positive company and is expected to immediately double the monthly revenue of Reklaim when the Transaction closes. The Transaction remains conditional on a number of customary factors, including, but not limited to, entering into a definitive agreement, final approval of the TSX Venture Exchange,...

Continue reading

Mindset Pharma Provides Strategic Intellectual Property License to Cybin

Licensing Subset of Mindset’s Family 1 Intellectual Property Underscores Strength of Mindset’s Portfolio and Business Strategy TORONTO, Sept. 27, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced an exclusive licensing agreement for Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) to acquire intellectual property rights for a subset of Mindset’s preclinical compounds (the “Agreement”). Under the terms of the Agreement, Cybin will license intellectual property related to preclinical compounds within Mindset’s “Family 1” portfolio, excluding MSP-1014, Mindset’s lead psychedelic drug candidate. “Over...

Continue reading

TransUnion Launches TruValidate Device Risk with Behavioral Analytics to Help Businesses Reduce Billions of Dollars in Fraud Losses from False Positives

Inclusion of NeuroID behavioral analytics helps provide immediate value during the application process CHICAGO, Sept. 27, 2022 (GLOBE NEWSWIRE) — To help limit the more than $100 billion1 of global sales revenue lost to false positives during the fraud detection process, TransUnion (NYSE: TRU) announced today the launch of TruValidate Device Risk with Behavioral Analytics. The solution is newly fortified by NeuroID’s behavioral analytics and aims to help businesses stop fraud – not good customers – based on device recognition, context, device and user behavior. The solution builds trusted connections by allowing users to join a global network of 6,000 fraud and security analysts, over 10 billion known devices and 100 million+ detailed known fraud reports. TransUnion’s TruValidate Device Risk with Behavioral Analytics is configurable,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.